D-penicillamine for primary biliary cirrhosis

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2004, Pages

  Gong, Yan ^a   Klingenberg, Sarah Louise ^b   Gluud, Christian ^b  

^a Cochrane Hepato Biliary Group ^*  (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PENICILLAMINE;

BILIARY CIRRHOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CHELATING AGENTS; HUMANS; LIVER CIRRHOSIS, BILIARY; PENICILLAMINE; RANDOMIZED CONTROLLED TRIALS;

EID: 16644369441     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004789.pub2     Document Type: Review

References (92)

1. Bassendine MF, Macklon AF, Mulcahy R, James OFW. Controlled trial of high and low dose D-penicillamine (DP) in primary biliary cirrhosis (PBC): results at three years (abstract). Gut 1982;23:A909.
2. Macklon AF, Bassendine MF, James OFW. Controlled trial of D-penicillamine in primary biliary cirrhosis: incidence of side effects and relation to dose (IASL abstract). Hepatology 1982;2:166.
3. Bodenheimer HC, Charland C, Thayer WR, Schaffner F, Staples PJ. Immunologic effects of penicillamine in patients with primary biliary cirrhosis. Hepatology 1983;3:845.
4. Bodenheimer HC, Colette CJr, Thayer WR, Schaffner FJr, Staples PJ. Effects of penicillamine on serum immunoglobulins and immune complex-reactive material in primary biliary cirrhosis. Gastroenterology 1985;88:412-7.
5. Bodenheimer HC, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985;5(6):1139-42.
6. Schaffner F, Sternlieb I, Sachs H. A two dose level randomized double blind controlled trial of penicillamine in primary biliary cirrhosis. Hepatology 1982;2(5):168.
7. Deering TB, Dickson ER, Fleming CR, Geall MG, McCall JT, Baggenstoss AH. Effect of D-penicillamine on copper retention in patients with primary biliary cirrhosis. Gastroenterology 1977;72:1208-12.
8. Dickson ER. The syndrome of primary biliary cirrhosis. Journal of Rheumatology 1981;8(Suppl 7):121-3.
9. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, et al. Trial of penicillamine in advanced primary biliary cirrhosis. New England Journal of Medicine 1985;312(16):1011-5. [MEDLINE: 85163601]
10. Dickson ER, Wiesner RH, Baldus WP, Fleming CR, Ludwig JL. D-penicillamine improves survival and retards histologic progression in primary biliary cirrhosis (abstract). Gastroenterology 1982;82:1225.
11. Locke GR, Therneau TM, Lugwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52-6.
12. Powell FC, Dickson ER. Primary biliary cirrhosis and lichen planus. Journal of the American Academy of Dermatology 1983;9(4):540-5.
13. Reed M. Penicillaine therapy 'encouraging' in primary biliary cirrhosis study. JAMA 1982;248:11-2.
14. Epstein O, Cook DG, Jain S, McIntyre N, Sherlock S. D-penicillamine and clinical trials in PBC (AASLD abstract). Hepatology 1984;4:1032.
15. Epstein O, Cook DG, Jain S, Sherlick S. D-penicillamine in primary biliary cirrhosis (PBC) - an untested (and untestable?) treatment (abstract). Gut 1984;25:A1134.
16. Epstein O, Jain S, Lee RG, Cook DG, Boss AM, Scheuer PJ, Scherlock S. D-penicillamine treatment improves survival in primary biliary cirrhosis (abstract). Gut 1981;22:A433.
17. Epstein O, Jain S, Lee RG, Cook DG, Boss AM, Scheuer PJ, et al. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1981;1:1275-7.
18. Epstein O, Villiers DD, Jain S, Potter B, Thomas H, Sherlock S. Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. The New England Journal of Medicine 1979;300:274-8.
19. Epstein O, Villiers DD, Jain S, Potter BJ, Thomas HC, Sherlock S. Effect of penicillamine on immune complexes and immunoglobulins in primary biliary cirrhosis (PBC) (abstract). Gut 1978;19:A994.
20. Jain S, McGee JO'D, Scheuer PJ, Samourian S, Sherlock S. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis and chronic active hepatitis (abstract). Digestion 1976;14:523.
21. Jain S, Scheuer PJ, Samourian S, McGee J, Sherlock S. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet 1977;16:831-4.
22. Jain S, Scheur PJ, Samourian S, McGee JO'D, Sherlock S. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis (abstract). Gut 1976;17:822.
23. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of D-penicillamine in primary biliary cirrhosis. New England Journal of Medicine 1982;306(6):319-26. [MEDLINE: 82103912]
24. Matloff DS, Resnick RH, Alpert E, Kaplan M. D-penicillamine does not alter the course of primary biliary cirrhosis (abstract). Clinical Research 1979;27:579A.
25. Neuberger J, Christensen E, Popper H, Portmann B, Caballeri J, Rodes J, et al. D-penicillamine in primary biliary cirrhosis: preliminary results of an international trial (EASL abstract). Liver 1984;4:G31.
26. Neuberger J, Christensen E, Popper H, Portmann B, Caballeri J, Rodes J, et al. D-penicillamine in primary biliary cirrhosis: preliminary results of an international trial (abstract). Gut 1983;24:A968.
27. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, et al. Double blind controlled trial of D-penicillamine in patients with primary biliary cirrhosis. Gut 1985;26(2):114-9. [MEDLINE: 85102903]
28. Taal BG, Schalm SW. Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy. Zeitschrift für Gastroenterologie 1985;23:228-34.
29. Taal BG, Schalm SW. Prednisone plus D-penicillamine, D-penicillamine and placebo compared in primary biliary cirrhosis syndrome (abstract). Gastroenterology 1981;80:1351.
30. Taal BG, Schalm SW, Ten Kate FWJ, Henegouwen GPB, Brandt KH. Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver 1983;3:345-52.
31. Taal BG, Schalm SW, Ten Kate FWJ, Van Berge Henegouwen GP, Brandt KH. A double-blind controlled trial of D-penicillamine for PBC: the dose dependent effect (abstract) [Een dubbelblind onderzoek met een controlegroep met D-penicillamine bij primaire biliaire cirrose: van de dosis afhankelijke effecten]. Nederlands Tijdschrift voor Geneeskunde 1982;126:547.
32. Gupta RC, Dickson ER, McDuffie FC, Baggenstoss AH. Immune complexes in primary biliary cirrhosis: high prevalence of circulating immune complexes in patients with associated autoimmune features. American Journal of Medicine 1982;73(2):192-8.
33. Savolainen ER, Miettinen TA, Pikkarainen P, Salaspuro MP, Kivirikko KI. Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis. Gut 1983;24:136-42.
34. Triger DR, Manifold IH, Cloke P, Underwood JCE. D-penicillamine in primary biliary cirrhosis: two year results of a single centre, double-blind controlled trial. Gut 1980;21(9):A919-20.
35. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.1[updated December 2003]. The Cochrane Library 2004, Issue 1.
36. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
37. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 1990;98:1567-71. [MEDLINE: 90249649]
38. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984;ii:1009. [MEDLINE: 85035466]
39. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-1101.
40. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis: a progress report on long-term follow-up and natural history. Gastroenterology 1985;89:267-71. [MEDLINE: 85231878]
41. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89:1084-91. [MEDLINE: 86006138]
42. Deeks JJ, Altman DG. Effect measures for meta-analysis of trials with binary outcomes. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. Second Edition. London: BMJ Books, 2001.
43. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examing heterogeneity and combing results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. Second Edition. London: BMJ Books, 2001.
44. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21:1575-1600.
45. Deiss A, Lynch RE, Lee GR, Cartwright GE. Long term therapy of Wilson's disease. Annals of Internal Medicine 1971;75:57-65.
46. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. [MEDLINE: 87291426]
47. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 87104256]
48. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 97456606]
49. Epstein O, De Villiers D, Jain S, Potter BJ, Thomas HC, Sherlock S. Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. New England Journal of Medicine 1979;300:274-8.
50. Epstein O, Chapman RWG, Lake-Bakaar G, Foo AY, Rosalki SB, Sherlock S, et al. The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology 1982;83(6):1177-82.
51. Fregeau D, Van de Water J, Danner D, Ansart T, Coppel R, Gershwin M. Antimitochondrial antibodies of primary biliary cirrhosis recongnize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha ketoacid dehydrogenase complex. Journal of Immunology 1989;142(11):3815-20. [BC86215 Hominidae]
52. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Statistics in Medicine 2002;21:1503-11.
53. Gluud C, Afroudakis AP, Caballeria J, Laskus T, Morgan M, Rueff B, et al. Diagnosis and treatment of alcoholic liver disease in Europe - First Report by the Gastroenterology Across Frontiers Panel. Gastroenterology International 1993;6:221-30.
54. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane Library 2002, Issue 2.
55. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-60.
56. Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976;70(5 Pt. 1):656-60. [MEDLINE: 76165921]
57. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
58. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. British Medical Journal 1999;319:670-4.
59. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986;91(6):1327-34. [MEDLINE: 87031329]
60. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: PAREXEL BARNETT, 1997.
61. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De-Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and negative primary biliary cirrhosis. Hepatology 1997;25(5):1090-5. [MEDLINE: 97286255]
62. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proceedings of the National Academy of Sciences of the United States of America 2001;98(3):831-6.
63. James O, Macklon AF, Waston AJ. Primary biliary cirrhosis - a revised clinical spectrum. Lancet 1981;1(8233):1278-81.
64. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991;101(5):1332-8. [MEDLINE: 92038733]
65. Kaplan MM. Primary biliary cirrhosis - a first step in prolonging survival. New England Journal of Medicine 1994;330(19):1386-7. [MEDLINE: 94203249]
66. Kaplan MM. Primary biliary cirrhosis. New England Journal of Medicine 1996;335(21):1570-80.
67. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gatroenterology 2000;119:1631-6.
68. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
69. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. American Journal of Gastroenterology 1995;90(2):247-9. [MEDLINE: 95149944]
70. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995;22(4 Pt 1):1158-62. [MEDLINE: 96029425]
71. Lipsky PE, Ziff M. Inhibition of human helper T cell function in vitro by D-penicillamine and copper sulfate. Journal of Clinical Investigation 1980;65:1069-76.
72. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20:641-54.
73. Mattalia A, Quaranta S, Leung PS, Bauducci M, Van-de-Water J, Calvo PL. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998;27(3):656-61. [MEDLINE: 98160326]
74. Metcalf J, Mitchison H, Palmer J, Jones D, Bassendine M, James O. Natural history of early primary biliary cirrhosis. Lancet 1996;348(9039):1399-402. [MEDLINE: 97091611]
75. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. Journal of Hepatology 1992;15(3):336-44. [MEDLINE: 93077929]
76. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 98417104]
77. Nimni ME, Deshmukh K, Gerth N. Collagen defect induced by D-penicillamine. Nature 1972;240:220-1.
78. Nyberg A, Loof L. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. Scandinavian Journal of Gastroenterology 1989;24(1):57-64. [MEDLINE: 89186599]
79. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES, et al. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996;24(5):1098-103. [MEDLINE: 97060347]
80. Prince M, Jones D, Metcalf J, Craig W, James O. Symptom development and prognosis of initially asymptomatic PBC. Hepatology 2000;32(4 Pt2):171A.
81. Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gatroenterology 2002;123:1044-51.
82. Scheuer P. Primary biliary cirrhosis. Proceedings of the Royal Society of Medicine 1967;60(12):1257-60. [MEDLINE: 68090739]
83. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 95123716]
84. Sternlieb I, Scheinberg IH. Penicillamine therapy for hepatolenticular degeneration. JAMA 1964;189:748-54.
85. Turchany JM, Uibo R, Kivik T, Van-de-Water J, Prindiville T, Coppel RL, et al. A study of antimitochondrial antibodies in a random population in Estonia. American Journal of Gastroenterology 1997;92(1):124-6. [MEDLINE: 97149143]
86. Van den Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. Journal of Hepatology 1986;3(3):310-7. [MEDLINE: 87167400]
87. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. European Journal of Gastroenterology and Hepatology 1999;11(8):817-20. [MEDLINE: 99442295]
88. Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid [see comments]. Gastroenterology 1995;108(5):1470-8. [MEDLINE: 95246981]
89. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis: trial design and preliminary report. Journal of Hepatology 1987;5(1):1-7. [MEDLINE: 88008957]
90. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. New England Journal of Medicine 1990;322(20):1419-24. [MEDLINE: 90231366]
91. Yamada G, Hyodo I, Tobe K, Mizuno M, Nishihara T, Kobayashi T, et al. Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis. Hepatology 1986;6(3):385-91. [MEDLINE: 86222190]
92. Gong Y, Klingenberg L, Gluud C. D-penicillamine vs placebo/no intervention in patients with primary biliary cirrhosis. Evidence-Based Gastroenterology 2007;8(2):41-2.